+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biodefense Market - Global Forecast 2026-2032- Product Image
Biodefense Market - Global Forecast 2026-2032- Product Image
Sale

Biodefense Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6082678
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biodefense Market is projected to reach USD 20.42 Billion in 2026. It is expected to continue growing at a CAGR of 7.55%, reaching USD 31.70 Billion by 2032.

Biodefense has moved from a niche national security function to a core pillar of public health resilience, pharmaceutical innovation, critical infrastructure protection, and emergency preparedness. Demand is shaped by recurring zoonotic outbreaks, antimicrobial resistance, laboratory biosecurity risks, climate-linked disease spread, and the need for faster medical countermeasure development across vaccines, diagnostics, therapeutics, decontamination systems, and personal protective equipment.

For industry leaders, the biodefense market is increasingly defined by readiness, scalable manufacturing, genomic surveillance, resilient supply chains, and trusted public-private partnerships.

Transformative Shifts in the Biodefense Landscape

The biodefense landscape is being reshaped by the convergence of national security, healthcare delivery, life sciences manufacturing, and digital public health. Governments are moving from reactive stockpiling toward integrated preparedness models that combine early warning systems, platform technologies, distributed manufacturing, interoperable data systems, and rapid procurement pathways.

Transformative shifts include the expansion of genomic epidemiology, the use of wastewater surveillance for population-level detection, and broader adoption of flexible vaccine and therapeutic platforms. Public agencies are also emphasizing supply chain resilience after COVID-19 exposed dependencies in active pharmaceutical ingredients, sterile fill-finish capacity, cold-chain logistics, diagnostic consumables, and workforce readiness. These shifts are increasing the strategic value of medical countermeasure platforms, biosurveillance tools, and response capabilities that can be adapted quickly across biological threat scenarios.

Cumulative Impact of Artificial Intelligence on Biodefense

Artificial intelligence is creating a cumulative impact across biodefense by improving signal detection, accelerating literature review, supporting pathogen surveillance, optimizing clinical trial operations, enhancing protein and antigen analysis, and strengthening logistics planning. AI-enabled analytics can help public health agencies detect anomalies across genomic, clinical, environmental, animal health, and mobility-linked datasets when governed by privacy, validation, cybersecurity, and transparency standards.

The most commercially relevant opportunity is not a single AI tool but an integrated intelligence layer across preparedness workflows. Organizations adopting responsible AI can shorten response timelines, prioritize countermeasure portfolios, model demand scenarios, improve allocation of scarce resources, and support regulatory documentation while maintaining compliance with biosafety, biosecurity, medical-device, and data-protection requirements. As AI adoption expands, explainability, human oversight, and validated performance will remain essential to trust in biodefense decision-making.

Key Regional Insights: Biodefense Demand Across Global Markets

Asia-Pacific is gaining strategic importance as China, India, Japan, South Korea, and Australia expand vaccine manufacturing, biosurveillance, genomic sequencing, and pandemic preparedness capabilities. The region’s exposure to emerging infectious diseases, dense urban centers, livestock-human interface risks, and cross-border trade routes supports sustained investment in diagnostics, sequencing networks, emergency operations, and rapid response platforms.

North America remains a major innovation and preparedness hub, supported by the U.S. Department of Health and Human Services, BARDA, CDC, NIH, Department of Defense programs, and Canada’s public health preparedness infrastructure. Regional priorities include next-generation medical countermeasures, domestic biomanufacturing, antimicrobial resistance response, and resilient supply chains. Latin America is advancing through PAHO-supported surveillance and national immunization systems, with Brazil and Mexico acting as anchors for regional vaccine, diagnostic, laboratory, and public health capacity.

Europe is driven by the European Commission, HERA, ECDC, national health security agencies, and strong pharmaceutical manufacturing networks, with growing emphasis on joint procurement, strategic stockpiling, cross-border surveillance, and preparedness exercises. The Middle East is investing in health security, laboratory capacity, emergency preparedness, digital health, and domestic manufacturing through national modernization programs and GCC coordination. Africa is strengthening continental surveillance and outbreak response through Africa CDC, national public health institutes, expanded genomic monitoring, and lessons from COVID-19, Ebola, mpox, and cholera responses.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN countries are strengthening public health emergency coordination, laboratory networks, workforce training, and cross-border disease surveillance as infectious disease risks intersect with high travel and trade intensity. The GCC is prioritizing health security as part of national transformation agendas, with investments in emergency preparedness, digital health infrastructure, local biomanufacturing capacity, and rapid response systems for mass gatherings and regional mobility.

The European Union has institutionalized preparedness through HERA, joint procurement, rescEU stockpiles, and ECDC coordination, creating a structured environment for medical countermeasures, surveillance technologies, and emergency logistics. BRICS countries bring scale, manufacturing depth, and large population health needs, particularly in vaccines, diagnostics, affordable therapeutics, genomic surveillance, and public health infrastructure.

G7 members continue to influence global biodefense financing, pandemic preparedness standards, and medical countermeasure innovation through initiatives such as the 100 Days Mission and support for global health security coordination. NATO’s relevance is rising through civil preparedness, resilience planning, medical support, and defense against chemical, biological, radiological, and nuclear threats, reinforcing demand for interoperable detection, protection, decontamination, logistics, and response systems.

Key Country Insights: Leading National Biodefense Markets

The United States leads global biodefense through BARDA, CDC, NIH, FDA, and Department of Defense programs, with strong demand for next-generation vaccines, diagnostics, antimicrobial solutions, therapeutics, biosurveillance, and rapid manufacturing. Canada is focused on public health preparedness, domestic biomanufacturing, and surveillance modernization, while Mexico’s role is tied to regional manufacturing, border health security, laboratory capacity, and emergency response. Brazil anchors Latin America through Fiocruz, Butantan Institute, national immunization infrastructure, and experience in arboviral disease surveillance.

In Europe, the United Kingdom is shaped by UKHSA capabilities, life sciences innovation, genomic surveillance expertise, and pandemic preparedness policy. Germany and France combine pharmaceutical strength, advanced laboratory networks, and EU-level coordination, while Italy and Spain contribute hospital systems, vaccine delivery infrastructure, public health surveillance, and emergency response capacity. Russia retains significant scientific, vaccine, and defense-related biodefense capabilities, though geopolitical constraints influence collaboration, procurement, and supply chains.

In Asia-Pacific, China’s scale, vaccine production capacity, sequencing infrastructure, and public health mobilization capabilities make it central to regional preparedness. India is a major supplier of vaccines and generics with expanding diagnostics and biomanufacturing capacity, Japan prioritizes advanced diagnostics, stockpiling, and health security, Australia combines biosecurity expertise with Indo-Pacific partnerships, and South Korea has developed strong infectious disease testing, biomanufacturing, digital response, and public health coordination capabilities.

Actionable Recommendations for Biodefense Industry Leaders

Industry leaders should prioritize platform-based medical countermeasures, validated AI analytics, interoperable surveillance tools, and manufacturing flexibility to compete in the next phase of biodefense. Organizations with capabilities in mRNA, recombinant proteins, viral vectors, monoclonal antibodies, broad-spectrum antivirals, antimicrobial solutions, rapid diagnostics, biosurveillance software, cold-chain systems, and protective equipment are well positioned for public procurement and strategic partnerships.

Vendors should build regulatory-ready evidence packages, diversify suppliers, secure cold-chain and fill-finish capacity, invest in cybersecurity for connected surveillance platforms, and align product roadmaps with national preparedness priorities. Partnerships with public health agencies, academic laboratories, contract development and manufacturing organizations, regional distributors, and emergency response networks can reduce time to deployment and improve resilience during demand surges.

Research Methodology and Data Validation

This executive summary is developed through structured secondary research using publicly available and verifiable sources, including WHO, CDC, ECDC, Africa CDC, PAHO, HERA, BARDA, NIH, FDA, NATO, World Bank, OECD, national health agencies, government budget documents, peer-reviewed journals, and official public health preparedness frameworks. Findings are triangulated across policy signals, procurement activity, disease surveillance priorities, manufacturing capacity, regulatory developments, and documented outbreak response needs.

The methodology emphasizes source reliability, recency, and relevance to the biodefense value chain. Market interpretation is based on observable indicators such as public funding commitments, preparedness strategies, medical countermeasure programs, outbreak response frameworks, biosurveillance investments, and regional health security initiatives rather than speculative claims. No market sizing, market share, or forecasting assumptions are used in this assessment.

Conclusion: Biodefense as a Strategic Growth Imperative

The biodefense market is entering a more strategic phase supported by government preparedness mandates, biotechnology innovation, AI-enabled intelligence, and stronger regional health security coordination. The sector’s value extends beyond emergency response to include routine surveillance, resilient manufacturing, medical countermeasure readiness, critical infrastructure protection, and national security planning.

Organizations that combine scientific credibility, regulatory discipline, scalable production, secure data practices, and trusted partnerships will be best positioned to capture long-term opportunities. As biological risks become more complex, the winning strategy will be preparedness by design rather than crisis-driven reaction.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Biodefense Market, by Product Type
7.1. Introduction
7.2. Decontamination Products
7.2.1. Disinfectants
7.2.2. PPE
7.3. Detection Devices
7.3.1. Biosensors
7.3.2. Pathogen Detection Systems
7.4. Therapeutics
7.4.1. Antiviral Therapies
7.4.2. Monoclonal Antibodies
7.5. Vaccines
7.5.1. Anthrax Vaccine
7.5.2. Botulism Vaccine
7.5.3. Smallpox Vaccine
8. Biodefense Market, by Pathogen Type
8.1. Introduction
8.2. Bacterial Agents
8.3. Toxins
8.4. Viral Agents
9. Biodefense Market, by Technology
9.1. Introduction
9.2. Immunoassays
9.3. Mass Spectrometry
9.4. Next Generation Sequencing
9.5. Polymerase Chain Reaction
10. Biodefense Market, by Application
10.1. Introduction
10.2. Detection & Diagnostics
10.3. Prevention
10.4. Treatment
11. Biodefense Market, by End User
11.1. Introduction
11.2. Academic & Research Institutes
11.3. Government & Defense Agencies
11.4. Hospitals & Clinics
11.5. Pharma & Biotech Companies
12. Biodefense Market, by Distribution Channel
12.1. Introduction
12.2. Offline Channels
12.3. Online Channels
13. Biodefense Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Biodefense Market, by Group
14.1. NATO
14.2. G7
14.3. European Union
14.4. BRICS
14.5. ASEAN
14.6. GCC
15. Biodefense Market, by Country
15.1. United States
15.2. China
15.3. Germany
15.4. Japan
15.5. India
15.6. United Kingdom
15.7. France
15.8. Canada
15.9. Italy
15.10. Australia
15.11. South Korea
15.12. Brazil
15.13. Mexico
15.14. Russia
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. Agilent Technologies, Inc.
17.3. Alnylam Pharmaceuticals, Inc.
17.4. Altimmune, Inc.
17.5. Appili Therapeutics by Aditxt, Inc.
17.6. Bavarian Nordic A/S
17.7. Bio-Rad Laboratories
17.8. Biofourmis Singapore Pte. Ltd.
17.9. Bruker Corporation
17.10. Dynavax Technologies Corporation
17.11. DynPort Vaccine Company LLC
17.12. Ecolab Inc.
17.13. Elusys Therapeutics, Inc.
17.14. Emergent BioSolutions Inc.
17.15. Ichor Medical Systems
17.16. Lucentix SA
17.17. Luminex Corporation by DiaSorin S.p.A.
17.18. Nova Biomedical Corporation
17.19. Novavax, Inc.
17.20. QIAGEN N.V.
17.21. SD BIOSENSOR
17.22. Siemens Healthcare
17.23. Siga Technologies, Inc.
17.24. Soligenix, Inc.
17.25. Strados Labs
17.26. Thermo Fisher Scientific
17.27. Tonix Pharmaceuticals
17.28. Xoma Corporation
List of Figures
FIGURE 1. GLOBAL BIODEFENSE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL BIODEFENSE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL BIODEFENSE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL BIODEFENSE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL BIODEFENSE MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BIODEFENSE MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL BIODEFENSE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL BIODEFENSE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL BIODEFENSE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL BIODEFENSE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL BIODEFENSE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL BIODEFENSE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL BIODEFENSE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL BIODEFENSE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL BIODEFENSE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL BIODEFENSE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL BIODEFENSE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL BIODEFENSE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL BIODEFENSE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL DECONTAMINATION PRODUCTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL DECONTAMINATION PRODUCTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL DECONTAMINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL DISINFECTANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL DISINFECTANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL DISINFECTANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL PPE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL PPE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL PPE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL DETECTION DEVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL DETECTION DEVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL DETECTION DEVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL BIOSENSORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL BIOSENSORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL BIOSENSORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL PATHOGEN DETECTION SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL PATHOGEN DETECTION SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL PATHOGEN DETECTION SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ANTIVIRAL THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ANTIVIRAL THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ANTIVIRAL THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ANTHRAX VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ANTHRAX VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ANTHRAX VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL BOTULISM VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL BOTULISM VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL BOTULISM VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL SMALLPOX VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SMALLPOX VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SMALLPOX VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL BACTERIAL AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL BACTERIAL AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL BACTERIAL AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL TOXINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL TOXINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL TOXINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL VIRAL AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL VIRAL AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL VIRAL AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL IMMUNOASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL IMMUNOASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL DETECTION & DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL DETECTION & DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL DETECTION & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL PREVENTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL PREVENTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL PREVENTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL GOVERNMENT & DEFENSE AGENCIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL GOVERNMENT & DEFENSE AGENCIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL GOVERNMENT & DEFENSE AGENCIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL PHARMA & BIOTECH COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL PHARMA & BIOTECH COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL PHARMA & BIOTECH COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL OFFLINE CHANNELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL OFFLINE CHANNELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL OFFLINE CHANNELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL ONLINE CHANNELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL ONLINE CHANNELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL ONLINE CHANNELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL BIODEFENSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 108. EUROPE BIODEFENSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. EUROPE BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 110. EUROPE BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 111. EUROPE BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 112. EUROPE BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 113. EUROPE BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 114. EUROPE BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 115. EUROPE BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 116. EUROPE BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 117. EUROPE BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 118. EUROPE BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA BIODEFENSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 124. NORTH AMERICA BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 125. NORTH AMERICA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 126. NORTH AMERICA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 127. NORTH AMERICA BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 128. NORTH AMERICA BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 129. NORTH AMERICA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA BIODEFENSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 135. LATIN AMERICA BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 136. LATIN AMERICA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 137. LATIN AMERICA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 138. LATIN AMERICA BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 139. LATIN AMERICA BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 140. LATIN AMERICA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 141. AFRICA BIODEFENSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 142. AFRICA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 143. AFRICA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 144. AFRICA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 145. AFRICA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 146. AFRICA BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 147. AFRICA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 148. AFRICA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 149. AFRICA BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 150. AFRICA BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 151. AFRICA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST BIODEFENSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 155. MIDDLE EAST BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 156. MIDDLE EAST BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 157. MIDDLE EAST BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 158. MIDDLE EAST BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 159. MIDDLE EAST BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 160. MIDDLE EAST BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 161. MIDDLE EAST BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 162. MIDDLE EAST BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL BIODEFENSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 164. NATO BIODEFENSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 165. NATO BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 166. NATO BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 167. NATO BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 168. NATO BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 169. NATO BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 170. NATO BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 171. NATO BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 172. NATO BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 173. NATO BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 174. NATO BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 175. G7 BIODEFENSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 176. G7 BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 177. G7 BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 178. G7 BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 179. G7 BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 180. G7 BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 181. G7 BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 182. G7 BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 183. G7 BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 184. G7 BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 185. G7 BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION BIODEFENSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 197. BRICS BIODEFENSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 198. BRICS BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 199. BRICS BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 200. BRICS BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 201. BRICS BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 202. BRICS BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 203. BRICS BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 204. BRICS BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 205. BRICS BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 206. BRICS BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 207. BRICS BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 208. ASEAN BIODEFENSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 209. ASEAN BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 210. ASEAN BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 211. ASEAN BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 212. ASEAN BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 213. ASEAN BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 214. ASEAN BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 215. ASEAN BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 216. ASEAN BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 217. ASEAN BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 218. ASEAN BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 219. GCC BIODEFENSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 220. GCC BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 221. GCC BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 222. GCC BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 223. GCC BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 224. GCC BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 225. GCC BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 226. GCC BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 227. GCC BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 228. GCC BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 229. GCC BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 230. GLOBAL BIODEFENSE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 231. UNITED STATES BIODEFENSE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 232. UNITED STATES BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 233. UNITED STATES BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 234. UNITED STATES BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 242. CHINA BIODEFENSE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 243. CHINA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 244. CHINA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 245. CHINA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 246. CHINA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 247. CHINA BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 248. CHINA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 249. CHINA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 250. CHINA BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 251. CHINA BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 252. CHINA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 253. GERMANY BIODEFENSE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 254. GERMANY BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 255. GERMANY BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 256. GERMANY BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 257. GERMANY BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 258. GERMANY BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 259. GERMANY BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 260. GERMANY BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 261. GERMANY BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 262. GERMANY BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 263. GERMANY BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 264. JAPAN BIODEFENSE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 265. JAPAN BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 266. JAPAN BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 267. JAPAN BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 268. JAPAN BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 269. JAPAN BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 270. JAPAN BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 271. JAPAN BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 272. JAPAN BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 273. JAPAN BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 274. JAPAN BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 275. INDIA BIODEFENSE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 276. INDIA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 277. INDIA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 278. INDIA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 279. INDIA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 280. INDIA BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 281. INDIA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 282. INDIA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 283. INDIA BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 284. INDIA BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 285. INDIA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM BIODEFENSE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 287. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 288. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 289. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 290. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 291. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 292. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 293. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 294. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 295. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 296. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 297. FRANCE BIODEFENSE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 298. FRANCE BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 299. FRANCE BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 300. FRANCE BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 301. FRANCE BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 302. FRANCE BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 303. FRANCE BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 304. FRANCE BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 305. FRANCE BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 306. FRANCE BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 307. FRANCE BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 308. CANADA BIODEFENSE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 309. CANADA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 310. CANADA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 311. CANADA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 312. CANADA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 313. CANADA BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 314. CANADA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 315. CANADA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 316. CANADA BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 317. CANADA BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 318. CANADA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 319. ITALY BIODEFENSE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 320. ITALY BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 321. ITALY BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 322. ITALY BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 323. ITALY BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 324. ITALY BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 325. ITALY BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 326. ITALY BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 327. ITALY BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 328. ITALY BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 329. ITALY BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 330. AUSTRALIA BIODEFENSE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 331. AUSTRALIA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 332. AUSTRALIA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 333. AUSTRALIA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 334. AUSTRALIA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 335. AUSTRALIA BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 336. AUSTRALIA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 337. AUSTRALIA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 338. AUSTRALIA BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 339. AUSTRALIA BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 340. AUSTRALIA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 341. SOUTH KOREA BIODEFENSE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 342. SOUTH KOREA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 343. SOUTH KOREA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 344. SOUTH KOREA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 345. SOUTH KOREA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 346. SOUTH KOREA BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 347. SOUTH KOREA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 348. SOUTH KOREA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 349. SOUTH KOREA BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 350. SOUTH KOREA BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 351. SOUTH KOREA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 352. BRAZIL BIODEFENSE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 353. BRAZIL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 354. BRAZIL BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 355. BRAZIL BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 356. BRAZIL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 357. BRAZIL BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 358. BRAZIL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 359. BRAZIL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 360. BRAZIL BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 361. BRAZIL BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 362. BRAZIL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 363. MEXICO BIODEFENSE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 364. MEXICO BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 365. MEXICO BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 366. MEXICO BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 367. MEXICO BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 368. MEXICO BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 369. MEXICO BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 370. MEXICO BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 371. MEXICO BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 372. MEXICO BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 373. MEXICO BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 374. RUSSIA BIODEFENSE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 375. RUSSIA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 376. RUSSIA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 377. RUSSIA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 378. RUSSIA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 379. RUSSIA BIODEFENSE MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 380. RUSSIA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 381. RUSSIA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 382. RUSSIA BIODEFENSE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 383. RUSSIA BIODEFENSE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 384. RUSSIA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 385. SPAIN BIODEFENSE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 386. SPAIN BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 387. SPAIN BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2017-2032 (USD MILLION)
TABLE 388. SPAIN BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2017-2032 (USD MILLION)
TABLE 389. SPAIN BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 390. SPAIN BIODEFENSE MA

Companies Mentioned

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Altimmune, Inc.
  • Appili Therapeutics by Aditxt, Inc.
  • Bavarian Nordic A/S
  • Bio-Rad Laboratories
  • Biofourmis Singapore Pte. Ltd.
  • Bruker Corporation
  • Dynavax Technologies Corporation
  • DynPort Vaccine Company LLC
  • Ecolab Inc.
  • Elusys Therapeutics, Inc.
  • Emergent BioSolutions Inc.
  • Ichor Medical Systems
  • Lucentix SA
  • Luminex Corporation by DiaSorin S.p.A.
  • Nova Biomedical Corporation
  • Novavax, Inc.
  • QIAGEN N.V.
  • SD BIOSENSOR
  • Siemens Healthcare
  • Siga Technologies, Inc.
  • Soligenix, Inc.
  • Strados Labs
  • Thermo Fisher Scientific
  • Tonix Pharmaceuticals
  • Xoma Corporation

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 20.42 Billion
Forecasted Market Value ( USD ) by 2032 $ 31.7 Billion
Compound Annual Growth Rate7.5%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Biodefense - Global Strategic Business Report - Product Image

Biodefense - Global Strategic Business Report

  • Report
  • 229 Pages
  • Global
From
Biodefense Market Insights, Competitive Landscape, and Market Forecast - 2033 - Product Image

Biodefense Market Insights, Competitive Landscape, and Market Forecast - 2033

  • Report
  • 192 Pages
  • Global
From
Biodefense Market Report 2026 - Product Image

Biodefense Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Biodefense Gene Synthesis Market Outlook 2026-2034: Market Share and Growth Analysis by Application (Vaccine Development, Pathogen Detection, Antimicrobial Resistance Studies, Others) - Product Image

Biodefense Gene Synthesis Market Outlook 2026-2034: Market Share and Growth Analysis by Application (Vaccine Development, Pathogen Detection, Antimicrobial Resistance Studies, Others)

  • Report
  • 160 Pages
  • Global
From
Bio-Detection - Global Strategic Business Report - Product Image

Bio-Detection - Global Strategic Business Report

  • Report
  • 281 Pages
  • Global
From

About the Biodefense Market

The Biodefense market is a sector of the biotechnology industry that focuses on the development of products and services to protect against biological threats. This includes the development of vaccines, diagnostics, and treatments for infectious diseases, as well as the development of countermeasures to protect against bioterrorism. Biodefense products are designed to protect against a wide range of biological agents, including bacteria, viruses, and toxins. The Biodefense market is driven by the need to protect against the increasing threat of biological agents, as well as the need to develop treatments for existing and emerging infectious diseases. Governments, healthcare organizations, and private companies are investing in the development of biodefense products and services. Some of the major companies in the Biodefense market include Emergent BioSolutions, GlaxoSmithKline, Johnson & Johnson, Merck, Novavax, Pfizer, and Sanofi. These companies are developing a range of products and services to protect against biological threats, including vaccines, diagnostics, and treatments. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.